ISSN: 1859 - 2872
Imaging characteristics and diagnostic value of 18F-FDG PET/CT in post-operative differentiated thyroid cancer patients with elevated serum thyroglobulin and negative 131I whole body scan
Main Article Content
Keywords
Abstract
Summary
Objective: To evaluate the imaging characteristics and diagnostic value of 18F-FDG PET/CT in post-operative differentiated thyroid cancer (DTC) patients with elevated serum thyroglobulin and negative 131I whole body scan. Subject and method: We performed a cross-sectional descriptive study on 109 post-surgical DTC patients. All patients underwent 18F-FDG PET/CT scan to look for recurrence/metastasis. PET/CT results were compared with hisopathology and clinical follow-up to determine its diagnostic values. Result: 294 lesions were identified in PET/CT with mean diameter and SUV were 14.0mm và 9.3g/ml, respectively. Lesions were most found in cervical lymphnode, mediastinum, thyroid bed and lung. PET/CT was positive in 78% of patients with true positive, false positive, true negative and false negative rates were 92.9%, 7.1%, 75% and 25%, respectively. Sensitivity, specificity and accuracy of PET/CT in detecting recurrent/metastatic DTC were 92.9%, 75% and 89%, respectively. SUVmax threshold of 5.9 ng/ml was the most suitable to determine recurrent/metastatic lesions in PET/CT. Conclusion: 18F-FDG PET/CT is a valuable imaging tool to diagnose recurrence/metastasis in DTC patient with elevated serum thyroglobulin and negative 131I whole body scan.
Keywords: 18F-FDG PET/CT, differentiated thyroid cancer, elevated thyroglobulin, negative 131I whole body scan.
Article Details
References
2. Basu S, Dandekar M, Joshi A, D'Cruz A (2015) Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): Considerations and challenges towards developing an appropriate roadmap. Eur J Nucl Med Mol Imaging 42: 1167-1171.
3. Caetano R, Bastos CRG, de Olivera IAG et al (2016) Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative 131I whole-body scan results: A meta-analysis. Head Neck 38: 316-327.
4. Chung JK, So Y, Lee JS et al (1999) Value of FDG PET in papillary thyroid carcinoma with negative l3lI whole-body scan. J NucI Med 40: 986-992.
5. Vural GU, Akkas BE, Erkamak N et al (2012) Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med 37: 953-959.
6. Kunawudhi A, Pak-art R, Keelawat S et al (2012) Detection of subcentimeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiated thyroid carcinoma and high serum thyroglobulin but negative 131I whole-body scan. Clin Nucl Med 37(6): 561-567.
7. Iagaru A, Kalinyak JE, McDougall R (2007) 18F-FDG PET/CT in the management of thyroid cancer. Clin Nucl Med 32: 690-695.
8. Na SJ, Yoo IR, O JH et al (2012) Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative 131I whole body scan: Evaluation by thyroglobulin level. Ann Nucl Med 26: 26-34.
9. Ozkan E, Aras G, Kucuk NO (2013) Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results. Clin Nucl Med 38: 326-331.
10. Ha LN, Bieu BQ, Son MH (2016) Value of dedicated head and neck 18F-FDG PET/CT protocol in detecting recurrent and metastatic lesions in post-surgical differentiated thyroid carcinoma patients with high serum thyroglobulin level and negative 131I whole-body scan. Asia Oceania J Nucl Med Biol 4(1): 12-18.
11. Stangierski A, Kaznowski J, Wolinski K et al (2016) The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan. Nucl Med Commun 37(9): 935-938.
12. Giovanella L, Trimboli P, Verburg FA et al (2013) Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 40: 874-880.
13. Choi SJ, Jung KP, Lee SS et al (2016) Clinical usefulness of F-18 FDG PET/CT in papillary thyroid cancer with negative radioiodine scan and elevated thyroglobulin level or positive anti-thyroglobulin antibody. Nucl Med Mol Imaging 50: 130-136.
Article Sidebar
